The New Rack-Scale Ready FlexTwin™ Systems Deliver Unprecedented Compute-Density in a Multi-Node Form Factor,with DLC dual CPUs up to 500W Each per Node,Front Node Access and Optimized Networking
SHANGHAI,Sept. 19,2024-- The Hybrid Cloud Infra Forum 2024,with the theme,"Dive into Cloud and Leap to a New Horizon",convened at HUAWEI CONNECT 2024 today. At the event,Shang Haifeng,CEO of
Canaan Partners Leads Round to Establish SAFIRE™ Technology as New Benchmark for Battery Safety KNOXVILLE,Tenn.,Sept. 20,2024-- Safire Technology Group,Inc. ("Safire Group"),today announce
Intel 471\'s CTI platform empowers organizations to navigate complex threats,improve visibility across digital assets,and proactively secure their environments against evolving cyber risks.
ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing.
J&T Express Achieves Strong Growth in 9.9 Mega Sales Through Refined Operations
HONG KONG,Sept. 19,2024-- J&T Global Express Limited("J&T Express" or "J&T" or "the Company",stock code: 01519.HK),a global logistics service provider,announ
Leadership Transition and Succession at Waterman Group
Nick Taylor to step down as CEO,Neil Humphrey named successor LONDON,Sept. 17,2024--After 42 years at Waterman,including 17 years as Chief Executive,Nick Taylor has decided to step down from the Water
Frost & Sullivan Recognizes Keysight's Network Packet Brokers with 2024 New Product Innovation Award
Keysight delivers scalable,high-performance,and highly flexible network visibility solutions for efficient network monitoring,threat detection,analysis and response
State Grid Dezhou Power Supply Company: Carefully Plan and Orderly Promote Autumn Inspection Work
DEZHOU,China,Sept. 18,2024-- Today,multiple maintenance tasks including replacement of the main transformer protection screen,inspection of protection devices,and switch transmission were carried out
TAIPEI and SAN DIEGO,Sept. 18,2024-- Senhwa Biosciences,Inc. (TPEx: 6492),a drug development company focusing on first-in-class therapeutics for oncology,rare diseases,and infectious diseases,today a